Showing 331-340 of 372 results for "".
- FDA Approves Novartis Drug Xolair for Chronic Idiopathic Urticariahttps://practicaldermatology.com/news/20140321-fda_approves_novartis_drug_xolair_for_chronic_idiopathic_urticaria/2459302/The FDA approved Xolair (Novartis, omalizumab) for the treatment of chronic idiopathic urticaria (CIU) for patients 12 years of age and older who remain symptomatic despite treatment with H1-antihistamine therapy. Xolair is not used to treat other forms of urticaria (hives) and is not for use in ch…
- Pierre Fabre Obtains FDA Approval to Market Hemangeol for the Treatment of Infantile Hemangiomahttps://practicaldermatology.com/news/20140319-pierre_fabre_obtains_fda_approval_to_market_hemangeol_for_the_treatment_of_infantile_hemangioma/2459311/Pierre Fabre Dermatologie has obtained marketing authorization from the FDA for the pediatric drug Hemangeol (propranolol hydrochloride), which is the first and only approved treatment for “proliferating infantile hemangioma requiring systemic therapy”. Hemangeol is an oral solution specially devel…
- Novartis Announces EU Approval of Xolair for Chronic Spontaneous Urticaria Patients Unresponsive to Antihistamineshttps://practicaldermatology.com/news/20140307-novartis_announces_eu_approval_of_xolair_for_chronic_spontaneous_urticaria_patients_unresponsive_to_antihistamines/2459322/The European Commission (EC) has approved the use of Xolair (omalizumab, Novartis) as an add-on therapy for the treatment of chronic spontaneous urticaria (CSU) in adult and adolescent (12 years and above) patients with inadequate response to H1-antihistamine treatment. The a…
- Mirvaso Approved by the European Commissionhttps://practicaldermatology.com/news/20140226-mirvaso_approved_by_the_european_commission/2459330/The European Commission has granted marketing authorization in Europe for Galderma's Mirvaso (brimonidine) 3 mg/g gel. Mirvaso, an alpha-2 adrenergic receptor agonist that acts rapidly and can last for up to 12 hours, is indicated for the symptomatic treatment of facial erythema of rosacea in adul…
- Ipsen Announces Clinical Results of Dysport Next Generationhttps://practicaldermatology.com/news/20140205-ipsen_announces_clinical_results_of_dysport_next_generation/2459348/Ipsen announced the results of the international Phase III clinical trial of Dysport Next Generation (DNG) in cervical dystonia and the results of the European Phase II clinical trial of DNG in glabellar lines. In the light of these results, Ipsen also announced its intention …
- Support Camp Discovery: Follow Us on Twitterhttps://practicaldermatology.com/news/20140130-support_camp_discovery_follow_us_on_twitter/2459354/Practical Dermatology® is excited to announce that we'll donate 20 cents for every new Twitter follower from Jan. 31, 2014 through March 14, 2014* to Camp Discovery. Simply follow @Practical_Derm on Twitter to help support Camp Discovery, which just celebrated 20 summers of camp trips. Camp Discov…
- Valeant Pharmaceuticals Completes Acquisition of Solta Medicalhttps://practicaldermatology.com/news/20140127-valeant_pharmaceuticals_completes_acquisition_of_solta_medical/2459359/Valeant Pharmaceuticals International, Inc. completed its acquisition of Solta Medical, Inc. at a price of $2.92 per share in cash, or approximately $250 million in the aggregate. On January 23, 2014, Valeant successfully completed the tender offer for all outstanding shares …
- Practical Dermatology® Magazine Names Neal Bhatia, MD, FAAD Co-Chief Medical Editorhttps://practicaldermatology.com/news/20140117-practical_dermatology_magazine_names_neal_bhatia_md_faad_co-chief_medical_editor/2459367/Neal Bhatia, MD, FAAD, San Diego-based dermatologist and well known lecturer and author, has been named Co-Chief Medical Editor of Practical Dermatology® magazine from Bryn Mawr Communications III, LLC. Now in it's 11th year of publication, Practical Dermatology® magazine continues to deliver depe…
- FDA Approves Combination Use of GSK's Mekinist® (trametinib) and Tafinlar® (dabrafenib)https://practicaldermatology.com/news/20140109-fda_approves_combination_use_of_gsks_mekinist_trametinib_and_tafinlar_dabrafenib/2459375/GlaxoSmithKline plc [LSE/NYSE: GSK] has received FDA approval of Mekinist® (trametinib) for use in combination with Tafinlar® (dabrafenib) for the treatment of patients with unresectable melanoma or metastatic melanoma with BRAF V600E or V600K mutations. These mutations must be detected by an FDA-a…
- FDA Approves Varithena to Treat Varicose Veinshttps://practicaldermatology.com/news/20131127-fda_approved_varithena_to_treat_varicose_veins/2459401/The FDA recently approved BTG plc's Varithena (polidocanol injectable foam) for the treatment of patients with incompetent veins and visible varicosities of the great saphenous vein (GSV) system. Varithena (formerly known as Varisolve PEM) is a pharmaceutical-grade, low-nitrogen, polidocanol foam …